Sodium phenylbutyrate in Huntington's disease: a dose-finding study
- PMID: 17702032
- DOI: 10.1002/mds.21632
Sodium phenylbutyrate in Huntington's disease: a dose-finding study
Abstract
Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose-finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose-escalation/de-escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose-response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well-tolerated in human HD.
2007 Movement Disorder Society
Similar articles
-
CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease.Mov Disord. 2006 Apr;21(4):530-3. doi: 10.1002/mds.20756. Mov Disord. 2006. PMID: 16258942 Clinical Trial.
-
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11023-8. doi: 10.1073/pnas.0504921102. Epub 2005 Jul 25. Proc Natl Acad Sci U S A. 2005. PMID: 16043692 Free PMC article.
-
Phase 2 study of sodium phenylbutyrate in ALS.Amyotroph Lateral Scler. 2009 Apr;10(2):99-106. doi: 10.1080/17482960802320487. Amyotroph Lateral Scler. 2009. PMID: 18688762 Clinical Trial.
-
Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.Carcinogenesis. 2009 Aug;30(8):1387-97. doi: 10.1093/carcin/bgp079. Epub 2009 Apr 7. Carcinogenesis. 2009. PMID: 19351790
-
The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test.Nat Clin Pract Neurol. 2007 Sep;3(9):517-25. doi: 10.1038/ncpneuro0606. Nat Clin Pract Neurol. 2007. PMID: 17805246 Review.
Cited by
-
Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.Parkinsons Dis. 2017;2017:5015307. doi: 10.1155/2017/5015307. Epub 2017 Aug 21. Parkinsons Dis. 2017. PMID: 28913005 Free PMC article. Review.
-
The promise and perils of HDAC inhibitors in neurodegeneration.Ann Clin Transl Neurol. 2015 Jan;2(1):79-101. doi: 10.1002/acn3.147. Epub 2014 Dec 3. Ann Clin Transl Neurol. 2015. PMID: 25642438 Free PMC article. Review.
-
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research.Int J Mol Sci. 2023 Aug 21;24(16):13021. doi: 10.3390/ijms241613021. Int J Mol Sci. 2023. PMID: 37629202 Free PMC article. Review.
-
Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds.Environ Mol Mutagen. 2009 Apr;50(3):213-21. doi: 10.1002/em.20454. Environ Mol Mutagen. 2009. PMID: 19197985 Free PMC article. Review.
-
Targeting histone deacetylases for the treatment of disease.J Cell Mol Med. 2009 May;13(5):826-52. doi: 10.1111/j.1582-4934.2008.00571.x. Epub 2008 Nov 3. J Cell Mol Med. 2009. PMID: 19175682 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
